Ligand Pharmaceuticals Incorporated
LGND
주식 순위
#3113
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
주가
$291.18
마지막 동기화: 2026-07-31
시가총액
$5.84B
변동 (1일)
-1.73%
변동 (1년)
55.99%
국가
US
거래 Ligand Pharmaceuticals Incorporated (LGND)
카테고리
Healthcare
Ligand Pharmaceuticals Incorporated (LGND)의 수익
Jun 2026 기준 수익 TTM: $237.96M
Ligand Pharmaceuticals Incorporated의 최신 재무 보고서에 따르면 회사의 현재 수익은 $237.96M입니다. 2023년에 회사는 $63.66M의 수익을 올렸으며 이는 2022년의 수익 $36.01M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Ligand Pharmaceuticals Incorporated의 수익 기록 (2000 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $237.96M | 9,350.44% |
| 2024 | $2.52M | -96.04% |
| 2023 | $63.66M | 76.78% |
| 2022 | $36.01M | -50.13% |
| 2021 | $72.21M | 5,488.62% |
| 2020 | $1.29M | -99.84% |
| 2019 | $796.64M | 359.61% |
| 2018 | $173.33M | 202.86% |
| 2017 | $57.23M | 618.98% |
| 2016 | $7.96M | -77.47% |
| 2015 | $35.33M | 212.59% |
| 2014 | $11.30M | 22.75% |
| 2013 | $9.21M | -338.21% |
| 2012 | $-3.87M | 31.91% |
| 2011 | $-2.93M | -80.98% |
| 2010 | $-15.40M | 56.03% |
| 2009 | $-9.87M | -89.88% |
| 2008 | $-97.52M | 82.42% |
| 2007 | $-53.46M | -69.33% |
| 2006 | $-174.27M | -579.56% |
| 2005 | $36.34M | -180.92% |
| 2004 | $-44.91M | 19.88% |
| 2003 | $-37.46M | 14.93% |
| 2002 | $-32.60M | 3.48% |
| 2001 | $-31.50M | -32.56% |
| 2000 | $-46.71M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 2,116.70% |
US
|
|
| $-3.09B | -1,397.27% |
US
|
|
| $-4.02B | -1,787.75% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 719.73% |
NL
|
